StockNews.AI

AI Market Monitoring While You Sleep

StockNews.AI analyzes financial news 24/7 and delivers alerts to help you spot opportunities and avoid losses — so you don't have to.

NVIDIA Announces Financial Results for First Quarter Fiscal 2025
StockNews AIanalyzing...

Backed By Jason Calacanis

Get Signals, Not Noise

Get Signals, Not Noise

Our AI analyzes corporate announcements instantly, providing you with actionable insights and alerts ahead of the market.
Read Less, Know More

Read Less, Know More

Tired of reading endless news and hitting paywalls? Our AI summarizes premium articles and extracts key insights—saving you 26 hours a month while keeping you better informed. Research finding:Read More
Stay Informed, Act Fast

Stay Informed, Act Fast

Easily setup customized filters, company screener, and monitor price-moving news of your portfolio

AI Event Agent's Top Alerts This Week

  • PROK
    GlobeNewsWire

    ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes

    1. REGEN-007 results show significant kidney function improvement in Group 1. 2. 78% reduction in eGFR decline was statistically significant (p<0.001). 3. Safety profile of rilparencel remains consistent with previous studies. 4. FDA Type B meeting planned to confirm eGFR slope as a surrogate endpoint. 5. ProKidney targets accelerated approval for rilparencel to address CKD market.

    +646.08%Current Return
    VS
    0%S&P 500
    $0.606507/08 07:07 AM EDTEvent Start

    $4.52507/09 01:31 PM EDTLatest Updated
    18 mins saved
    Full Article
  • LGPS
    Business Wire

    LogProstyle Inc. Announces Approval of Share Repurchase Program by the Board of Directors

    1. LogProstyle announced a share repurchase program for $543,455. 2. Program includes repurchase of up to 1,086,910 common shares. 3. Acquisitions are set from July 1, 2025, to June 30, 2026. 4. The program aims to enhance shareholder value through disciplined capital allocation. 5. LGPS commits to innovative and sustainable lifestyle projects.

    +90.68%Current Return
    VS
    0%S&P 500
    $0.8407/07 08:46 AM EDTEvent Start

    $1.601707/08 03:21 PM EDTLatest Updated
    4 mins saved
    Full Article
  • LGPS
    Business Wire

    LogProstyle Reports Fiscal Year 2025 Results

    1. LGPS reported a 46% revenue increase in fiscal year 2025. 2. Net income more than doubled, reaching JPY754 million (US$5 million). 3. Real estate revenue surged 52%, driven by increased unit sales. 4. Company's hotel revenue rose 20% with improved occupancy rates. 5. LGPS expanded globally with new US and Dubai subsidiaries.

    +90.48%Current Return
    VS
    0%S&P 500
    $0.8407/07 08:21 AM EDTEvent Start

    $1.607/08 01:59 PM EDTLatest Updated
    12 mins saved
    Full Article
  • RXST
    GlobeNewsWire

    RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance

    1. RxSight expects Q2 2025 revenue of $33.6M, down 4% YoY. 2. LAL sales fell 1%; LDD sales dropped 45% Q/Q. 3. 2025 revenue guidance reduced to $120M-$130M from $160M-$175M. 4. Gross margin guidance increased to 72%-74%; operating expenses raised. 5. CEO emphasizes customer support for better outcomes and adoption.

    -37.79%Current Return
    VS
    0%S&P 500
    $12.7807/08 04:07 PM EDTEvent Start

    $7.9507/09 10:46 PM EDTLatest Updated
    10 mins saved
    Full Article
  • RYTM
    GlobeNewsWire

    Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

    1. Bivamelagon achieved significant BMI reductions of -9.3% and -7.7%. 2. Post-hoc analysis shows bivamelagon's effectiveness comparable to setmelanotide. 3. Patients reported a mean reduction of -2.8 points in hunger scores. 4. Rhythm plans to request FDA meeting for Phase 3 trial in obesity. 5. Company will present findings at The Endocrine Society’s Annual Meeting.

    +35.66%Current Return
    VS
    0%S&P 500
    $65.1407/09 08:05 AM EDTEvent Start

    $88.369307/10 02:31 PM EDTLatest Updated
    18 mins saved
    Full Article
  • COGT
    GlobeNewsWire

    Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

    1. Bezuclastinib shows significant symptom score improvement in NonAdvSM patients. 2. 87.4% of treated patients had over 50% reduction in serum tryptase. 3. NDA submission for bezuclastinib to FDA expected by end of 2025. 4. Cogent maintains a strong financial position with $237 million cash. 5. Top-line results from related trials PEAK and APEX expected in late 2025.

    +31.4%Current Return
    VS
    0%S&P 500
    $7.5807/07 07:14 AM EDTEvent Start

    $9.9607/08 01:37 PM EDTLatest Updated
    13 mins saved
    Full Article
  • KLG
    PRNewsWire

    FERRERO TO ACQUIRE WK KELLOGG CO

    1. Ferrero to acquire WK Kellogg Co for $23.00 per share cash. 2. Transaction reflects 40% premium over recent trading price of KLG shares. 3. Acquisition enhances Ferrero's portfolio with iconic breakfast cereal brands. 4. WK Kellogg Co expects net sales of $610-615 million for Q2 2025. 5. The deal is likely to close in the second half of 2025.

    +30.63%Current Return
    VS
    0%S&P 500
    $17.507/10 09:04 AM EDTEvent Start

    $22.8607/10 08:55 PM EDTLatest Updated
    26 mins saved
    Full Article
  • KLG
    CNBC

    Cereal maker WK Kellogg shares jump 50% on report of possible $3 billion deal with Ferrero

    1. WK Kellogg shares jumped over 50% on acquisition news. 2. Ferrero may finalize a $3 billion purchase of WK Kellogg soon. 3. Kellanova separated from WK Kellogg in 2023 amidst market shifts. 4. Consumer preferences are shifting towards healthier breakfast options. 5. The deal signifies increasing consolidation in the packaged food sector.

    +30.63%Current Return
    VS
    0%S&P 500
    $17.507/09 06:34 PM EDTEvent Start

    $22.8607/10 08:55 PM EDTLatest Updated
    3 mins saved
    Full Article
  • KALV
    Business Wire

    KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

    1. KALV's EKTERLY approved as first oral on-demand HAE treatment. 2. EKTERLY offers rapid symptom relief, transforming HAE management. 3. Launch of EKTERLY begins immediately; prescriptions available today. 4. Significant safety profile established through robust clinical trials. 5. KalVista emphasizes commitment to HAE community via patient support program.

    +25.41%Current Return
    VS
    0%S&P 500
    $11.9807/07 06:39 AM EDTEvent Start

    $15.023607/08 01:08 PM EDTLatest Updated
    12 mins saved
    Full Article
  • HELE
    Business Wire

    Helen of Troy Limited Reports First Quarter Fiscal 2026 Results

    1. HELE reported a 10.8% drop in net sales to $371.7 million. 2. GAAP loss per share reached $19.65, significantly down from earnings per share. 3. Non-cash asset impairment of $414.4 million heavily impacted operating results. 4. CEO search is ongoing, with interim CEO focusing on core business improvements. 5. Tariff impacts accounted for significant revenue decline; mitigation efforts remain in progress.

    -22.71%Current Return
    VS
    0%S&P 500
    $3107/10 06:56 AM EDTEvent Start

    $23.9607/10 08:42 PM EDTLatest Updated
    30 mins saved
    Full Article

What We Provide

70%
10K+
8K+

What Ours Users Say

BrandonBrandon, Morgan Stanley

I find the AI indicators such as “Very bullish” or “Very bearish” particularly helpful. The AI generally provides valuable clarity, especially when I m uncertain.

ChristyChristy, Retail Investor

Was skeptical at first, but I appreciate how well-formatted and easy-to-read the bullet points are—they make it simple to digest the key insights quickly.

RichardRichard, Bank of America

While platforms like Bloomberg are valuable for delivering breaking news, they often lack a rating system and the sheer volume of news make it difficult to focus on what truly matters.

More Users From

Find Opportunities 10X Faster

14-Days Money-Back Gaurentee

Frequently Asked Questions